Treatment of nonendocrine gastrointestinal disorders with octreotide acetate.
Somatostatin and its longer-acting analog, octreotide acetate, can be used effectively for the treatment of nonendocrine gastrointestinal disorders. Octreotide has been shown to decrease pancreatic fistula output by suppressing exocrine pancreatic function. We believe that octreotide acetate may be useful to prophylaxis against the development of pancreatic fistulas following pancreatic resection and may reduce the enzymatic and volume output of established pancreatic fistulas. We also have shown that administration of octreotide acetate 2 hours before a high carbohydrate test meal reduces gut peptide levels, which increase following meal ingestion in patients with the dumping syndrome. Reduction of circulating peptides in these patients may slow gut motility and improve glucose regulation, thus, providing relief of postvagotomy dumping symptoms.
Woltering
E A
EA
Department of Surgery, Oregon Health Sciences University, Portland 97201.
O'Dorisio
T M
TM
Williams
S T
ST
Lebrado
L
L
Fletcher
W S
WS
D004377:Dumping Syndrome / Q000188:drug therapy*; D005767:Gastrointestinal Diseases / Q000188:drug therapy*; D005769:Gastrointestinal Motility / Q000187:drug effects; D005947:Glucose / Q000378:metabolism; D006801:Humans; D015282:Octreotide / Q000627:therapeutic use*; D010455:Peptides / Q000378:metabolism; D013004:Somatostatin / Q000627:therapeutic use
D010455:Peptides; D013004:Somatostatin; D005947:Glucose; D015282:Octreotide